Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
65.38
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
8,931,620
CFO
$-83.75 Mln
EBITDA
$-60.27 Mln
Net Profit
$-171.09 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
| 32.9 | 16.5 | -25.9 | -35.5 | -41.3 | -48.8 | -61.9 |
|
BSE Sensex*
| 3.5 | 1.9 | 7.5 | 9.5 | 14.2 | 21.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
| -74.8 | -46.3 | -67.8 | 30.0 | -71.9 | -57.8 | -38.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Predictive Oncology (POAI)
|
1.1 | 8.9 | 1.4 | -8.5 | -564.2 | -- | -- | 1.4 |
| 12.6 | 9,178.9 | 6,685.2 | 715.6 | 16.4 | 12.3 | 13 | 1.5 | |
| 250.1 | 7,103.9 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 228.0 | 6,651.1 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 59.3 | 8,339.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 46 | 2.0 | |
| 72.1 | 9,141.6 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.8 | 2.8 | |
| 149.4 | 8,437.6 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 8.8 | |
| 96.5 | 5,840.8 | 1,387.9 | 122.3 | 13.3 | 8.9 | 48.4 | 4.1 | |
| 270.4 | 10,887.0 | 1,240.1 | 42.2 | 4.1 | 3.6 | 262.7 | 9.0 | |
| 120.2 | 7,089.8 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment... provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania. Address: 91 43rd Street, Pittsburgh, PA, United States, 15201 Read more
CEO & Chairman
Mr. Raymond F. Vennare
CEO & Chairman
Mr. Raymond F. Vennare
Headquarters
Pittsburgh, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Predictive Oncology Inc (POAI) stood at $ 9 Mln as on 31-Mar-25
The share price of Predictive Oncology Inc (POAI) is $1.09 (NASDAQ) as of 21-May-2025 16:17 EDT. Predictive Oncology Inc (POAI) has given a return of -41.34% in the last 3 years.
Predictive Oncology Inc (POAI) has a market capitalisation of $ 9 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Predictive Oncology Inc (POAI) is 1.43 times as on 20-May-2025, a 60% discount to its peers’ median range of 3.58 times.
Since, TTM earnings of Predictive Oncology Inc (POAI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Predictive Oncology Inc (POAI) and enter the required number of quantities and click on buy to purchase the shares of Predictive Oncology Inc (POAI).
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania. Address: 91 43rd Street, Pittsburgh, PA, United States, 15201
The CEO & director of Mr. Raymond F. Vennare. is Predictive Oncology Inc (POAI), and CFO & Sr. VP is Mr. Raymond F. Vennare.
There is no promoter pledging in Predictive Oncology Inc (POAI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,119
|
|
|
876
|
|
|
858
|
|
|
830
|
|
|
787
|
|
|
719
|
|
|
687
|
|
|
687
|
|
|
573
|
| Predictive Oncology Inc. (POAI) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-564.23
|
|
Net Margin(%)
|
-627.31
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Predictive Oncology Inc (POAI) was $0 Mln.
$-0.01
(
